<DOC>
	<DOC>NCT00370097</DOC>
	<brief_summary>The purpose of this study is to address an Food Drug and Administration (FDA) request to provide safety data in pre-asthmatic patients, ages 6 months to &lt;12 months, following administration of fluticasone propionate HFA.</brief_summary>
	<brief_title>FLOVENT Hydrofluoroalkane (HFA) In 6-12 Month Old Subjects</brief_title>
	<detailed_description>A repeat-dose, open-label, 2-session study to assess the systemic exposure to, and pharmacodynamics of, fluticasone propionate HFA inhalation aerosol 88mcg administered twice-daily for 28 days delivered via an MDI and valved holding chamber with infant facemask to subjects ages 6 months to &lt;12 months who have experienced 2 or more wheezing episodes in the preceding 6 months</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Subjects who have experienced 2 or more wheezing episodes in the previous 6 months. Subjects may not have taken any corticosteroids in the 4 weeks prior to dosing Parents/guardians should be able to read and comprehend diary information collected throughout the study Parents must be able to demonstrate the ability to use the facemask and spacer used to administer study drug Exclusion criteria: Subjects who weigh less than 7 kg Subjects who are taking any drugs that inhibit or induce the cytochrome P450 isoform Any parents who have a history of psychiatric disease, intellectual deficiency, substance abuse that would compromise the validity of the consent</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Asthma infants FLOVENT spacer</keyword>
</DOC>